Related Experiment Video
Updated: Apr 3, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
SETD1A modulates cell cycle progression through a miRNA network that regulates p53 target genes
Ken Tajima1, Toshifumi Yae1, Sarah Javaid1
1Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
Abstract:
Expression of the p53-inducible antiproliferative gene BTG2 is suppressed in many cancers in the absence of inactivating gene mutations, suggesting alternative mechanisms of silencing. Using a shRNA screen targeting 43 histone lysine methyltransferases (KMTs), we show that SETD1A suppresses BTG2 expression through its induction of several BTG2-targeting miRNAs. This indirect but highly specific mechanism, by which a chromatin regulator that mediates transcriptional activating marks can lead to the downregulation of a critical effector gene, is shared with multiple genes in the p53 pathway. Through such miRNA-dependent effects, SETD1A regulates cell cycle progression in vitro and modulates tumorigenesis in mouse xenograft models. Together, these observations help explain the remarkably specific genetic consequences associated with alterations in generic chromatin modulators in cancer.
Insights
The histone methyltransferase SETD1A suppresses the cancer gene BTG2 indirectly via microRNAs, impacting cell cycle and tumor growth. This reveals a novel mechanism for gene silencing in cancer.
Area of Science:
- Cancer Biology
- Epigenetics
- Gene Regulation
Background:
- The antiproliferative gene BTG2 is often downregulated in cancers without direct mutations.
- Alternative gene silencing mechanisms for BTG2 are suggested.
- Histone lysine methyltransferases (KMTs) are implicated in cancer development.
Purpose of the Study:
- To identify the mechanism suppressing BTG2 expression in cancer.
- To investigate the role of KMTs in regulating BTG2.
- To understand how chromatin regulators impact cancer-related genes.
Main Methods:
- shRNA screen targeting 43 histone lysine methyltransferases (KMTs).
- Analysis of miRNA induction and gene expression.
- In vitro cell cycle assays.
- Mouse xenograft models for tumorigenesis studies.
Main Results:
- SETD1A was identified as a suppressor of BTG2 expression.
- SETD1A induces BTG2-targeting microRNAs (miRNAs), leading to gene downregulation.
- This indirect miRNA-dependent mechanism affects multiple p53 pathway genes.
- SETD1A regulates cell cycle progression and modulates tumorigenesis in vivo.
Conclusions:
- SETD1A suppresses BTG2 via an indirect miRNA-dependent mechanism.
- This pathway explains specific genetic consequences of chromatin modulator alterations in cancer.
- Findings elucidate a novel epigenetic regulation of tumor suppressor genes.
More Related Videos
Related Concept Videos
Negative Regulator Molecules
Abnormal Proliferation
Inhibition of Cdk Activity
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle
Molecular Factors Affecting Cell Division
Several proteins function as internal regulators to ensure each cell cycle stage is completed faithfully before proceeding to the next. Regulator molecules may act directly or influence the activity or production of other...

